Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.49 |
| ▸ | HRH2 | P25021 | 5/20 | 0.46 |
| ▸ | HRH1 | P35367 | 5/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917378 | 1.00 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL9917377 | 1.00 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL22281966 | 0.90 | HTR1A (0.54) | HRH3HRH2HRH1HTR1A | |
| SCHEMBL20729427 | 0.90 | HTR1A (0.54) | HRH3HRH2HRH1HTR1A | |
| SCHEMBL20729452 | 0.90 | HTR1A (0.54) | HRH3HRH2HRH1HTR1A | |
| SCHEMBL8501119 | 0.90 | HRH3 (0.43) | HRH3HRH2HRH1 | |
| SCHEMBL9911416 | 0.90 | LTA4H (0.43) | HRH3HRH2HRH1HTR1ALTA4H | |
| SCHEMBL12872466 | 0.90 | LTA4H (0.43) | HRH3HRH2HRH1HTR1ALTA4H | |
| SCHEMBL9911415 | 0.90 | LTA4H (0.43) | HRH3HRH2HRH1HTR1ALTA4H | |
| SCHEMBL26239366 | 0.87 | HRH3 (0.47) | HRH3HRH2HRH1HTR1APDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11691985-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4105203-A1 | SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS | Epizyme Inc (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708326-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | HRH3 143/4885HRH2 110/4885HRH1 166/4885 |
| US-11691985-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | HRH3 162/4885HRH2 158/4885HRH1 234/4885 |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | HNMT, EHMT2, SHMT2 | HRH3 641/4885HRH2 1094/4885HRH1 1475/4885 |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | SHMT1, BHMT, EHMT2 | HRH3 1654/4885HRH2 2338/4885HRH1 2096/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | HRH3 2154/4885HRH2 2900/4885HRH1 3557/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | HRH3 2154/4885HRH2 2900/4885HRH1 3557/4885 |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | HRH3 11/4885HRH2 21/4885HRH1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.